Deutsche Bank AG Invests $3.07 Million in Relay Therapeutics, Inc. $RLAY

Key Points

• Deutsche Bank acquired 164,036 shares of Relay Therapeutics in the second quarter, worth approximately $3.07 million and representing about 0.09% of the company. Institutional investors and hedge funds collectively own 96.98% of RLAY.
• Relay Therapeutics reported a quarterly loss of $0.41 per share, missing the $0.39 consensus estimate, while revenue of $0.35 million fell short of the $0.96 million forecast. Analysts expect a full-year loss of $1.61 per share.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $25.92 price target versus a recent share price of $19.46, although one firm downgraded the stock to “Sell.”

Deutsche Bank AG purchased a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 164,036 shares of the company's stock, valued at approximately $3,069,000. Deutsche Bank AG owned about 0.09% of Relay Therapeutics as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. KBC Group NV acquired a new position in shares of Relay Therapeutics during the first quarter valued at approximately $34,000. Torren Management LLC purchased a new position in shares of Relay Therapeutics in the fourth quarter valued at approximately $30,000. Smartleaf Asset Management LLC boosted its stake in shares of Relay Therapeutics by 288.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company's stock worth $37,000 after acquiring an additional 3,287 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Relay Therapeutics during the fourth quarter worth approximately $46,000. Finally, Abel Hall LLC purchased a new stake in shares of Relay Therapeutics during the third quarter worth approximately $58,000. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Relay Therapeutics Price Performance

Shares of NASDAQ RLAY opened at $19.46 on Thursday. The company has a market capitalization of $4.26 billion, a P/E ratio of -12.39 and a beta of 1.69. The company has a 50 day simple moving average of $19.14 and a 200-day simple moving average of $14.64. Relay Therapeutics, Inc. has a 1 year low of $3.49 and a 1 year high of $21.27.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). The company had revenue of $0.35 million during the quarter, compared to analysts' expectations of $0.96 million. As a group, research analysts expect that Relay Therapeutics, Inc. will post -1.61 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on RLAY shares. Raymond James Financial restated a "strong-buy" rating on shares of Relay Therapeutics in a report on Tuesday, May 19th. The Goldman Sachs Group increased their target price on shares of Relay Therapeutics from $22.00 to $31.00 and gave the company a "buy" rating in a research report on Tuesday, July 21st. Wall Street Zen downgraded shares of Relay Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Canaccord Genuity Group assumed coverage on shares of Relay Therapeutics in a research report on Thursday, July 16th. They set a "buy" rating and a $29.00 price target on the stock. Finally, Zacks Research raised shares of Relay Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 20th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $25.92.

Insiders Place Their Bets

In other news, CFO Thomas Catinazzo sold 1,459 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total transaction of $27,151.99. Following the completion of the transaction, the chief financial officer directly owned 158,285 shares in the company, valued at approximately $2,945,683.85. This represents a 0.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Donald A. Bergstrom sold 2,237 shares of the firm's stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total value of $41,630.57. Following the sale, the insider directly owned 407,660 shares of the company's stock, valued at $7,586,552.60. The trade was a 0.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 409,639 shares of company stock worth $7,233,399 over the last ninety days. Company insiders own 5.04% of the company's stock.

Relay Therapeutics Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

Want to see what other hedge funds are holding RLAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source